Insider Selling: Phreesia, Inc. (NYSE:PHR) General Counsel Sells 3,496 Shares of Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 3,496 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $29.72, for a total transaction of $103,901.12. Following the completion of the sale, the general counsel now directly owns 142,630 shares in the company, valued at $4,238,963.60. This represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Phreesia Trading Down 4.0 %

Shares of Phreesia stock traded down $1.20 on Thursday, hitting $28.49. The stock had a trading volume of 346,852 shares, compared to its average volume of 382,462. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -19.38 and a beta of 0.96. The stock’s 50-day simple moving average is $27.14 and its two-hundred day simple moving average is $23.77.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. During the same quarter last year, the business earned ($0.58) earnings per share. The business’s revenue was up 16.6% on a year-over-year basis. As a group, sell-side analysts predict that Phreesia, Inc. will post -1.1 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PHR shares. Robert W. Baird lowered their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Citigroup increased their price target on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. JMP Securities reiterated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Piper Sandler reiterated an “overweight” rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $29.00 price target on shares of Phreesia in a research report on Friday, January 10th. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia has an average rating of “Buy” and an average price target of $31.15.

Institutional Trading of Phreesia

Large investors have recently added to or reduced their stakes in the stock. Versor Investments LP bought a new stake in Phreesia in the third quarter valued at $694,000. Zacks Investment Management bought a new stake in Phreesia in the third quarter valued at $631,000. State Street Corp boosted its holdings in Phreesia by 7.1% in the third quarter. State Street Corp now owns 1,327,586 shares of the company’s stock valued at $30,256,000 after acquiring an additional 88,517 shares in the last quarter. Wesbanco Bank Inc. boosted its holdings in Phreesia by 76.9% in the fourth quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company’s stock valued at $1,157,000 after acquiring an additional 20,000 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Phreesia by 83.6% in the third quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after acquiring an additional 43,225 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.